Relative Bioavailability and Food Effect Study in Healthy Subjects Administered Two Different Formulations of LY3202626

Trial Profile

Relative Bioavailability and Food Effect Study in Healthy Subjects Administered Two Different Formulations of LY3202626

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs LY 3202626 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 19 Jun 2017 Status changed from recruiting to completed.
    • 24 Feb 2017 Planned End Date changed from 1 Mar 2017 to 4 Apr 2017.
    • 24 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 4 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top